Predictors of actinic keratosis count in patients with multiple keratinocyte carcinomas: A cross-sectional study To the Editor: Actinic keratoses (AKs) are common, are costly, and have the potential for malignant transformation to keratinocyte carcinoma (KC), 1 ie, cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). We sought to determine predictors of AK in patients with a history of multiple KCs, as AKs are more likely to progress to KC in this high-risk population. 1 Predictors of AK count were explored crosssectionally using prerandomization baseline data from 2 trials of veterans with 2 or more KCs in the past 5 years (Department of Veterans Affairs [VA] KC Chemoprevention Trial, n ¼ 932 2 ; and VA Topical Tretinoin Chemoprevention Trial, n ¼ 1131). 3 Univariable and multivariable analyses using Stata software (StataCorp LP, College Station, TX) were performed to elucidate associations between AK count on the face/ears (assessed by study dermatologists) and demographic/health-related factors (selfreported) and KCs in the past 5 years ( from medical records). Baseline AKs and prior KCs were analyzed in quintiles to minimize impact of extreme values. VA Institutional Review Boards approved both trials, participants gave written consent, and Declaration of Helsinki protocols were followed.
In both studies of predominantly elderly male participants (Table I) , greater baseline AK count on the face/ears was strongly associated (P \ .01) with older age, lower latitude of VA Medical Center, greater sun sensitivity, past 5-fluorouracil use, and higher numbers of prior SCCs (invasive [ in situ), but not BCCs. In the VA Topical Tretinoin Chemoprevention Trial, photodamage, focal dermatitis, and rosacea with rhinophyma were also associated with increased AKs (Tables II and III) . More AKs were on the left face/ear perhaps because of increased ultraviolet radiation while driving (data not shown). Study strengths include 2 large study groups and reliable records of past KCs. Limitations include selfreported data, a homogenous study population, and limited reliability of counting AKs (although this was improved with training sessions to help standardize technique).
AK risk factors reported in general populations are similar to those identified in our high-risk groups. 4 However, Flohil et al 4 found that increased AK count was also associated with prior BCCs, but included cancers diagnosed over the past 20 years. AKs are known to progress to SCC, but their relationship with BCC remains unclear.
It is uncertain why focal dermatitis and rosacea with rhinophyma might be related to an increased risk of AK. Perhaps such areas of increased inflammation are more susceptible to keratinocyte dysplasia, just as areas of chronic inflammation can lead to SCC.
Our results confirm that AKs are associated with chronic sun damage, and highlight the relationship between AKs and SCC independent of susceptibility to ultraviolet damage. (AKs were associated with prior SCCs even when we controlled for sun sensitivity.) However, in addition to being associated with prior skin cancers, AKs have been associated with a 6-fold increased risk of future skin cancers arising outside of AK lesions. 5 Thus, predictors of AK may also be predictors of prospective skin cancers.
Although risk factors for AKs in a high-risk population are similar to those in the general population, they should raise more concern as AKs in this group are more likely to progress to KC. The following variables were excluded from this table because they did not have significant associations with baseline AK quintile: race, marital status, Medicare enrollment status, hat use, sunscreen use on face and/or ears, sunscreen sun-protection factor on face and/or ears, smoking status, eyeglasses use, general dermatitis, rosacea with inflammatory papules, psoriasis, eczema, acne, diabetes, congestive heart failure, nonskin cancer, ability to bathe, ability to manage money, ability to walk, and ability to push/pull heavy objects. AK, Actinic keratosis; BCC, basal cell carcinoma; COPD, chronic obstructive pulmonary disease; FU, fluorouracil; KC, keratinocyte carcinoma; n/a, not applicable; SCC, squamous cell carcinoma; SCCIS, squamous cell carcinoma in situ; VA, We have conducted a single-treatment, short-term follow-up, case series trial as proof of concept for the use of NTAP in the treatment of AKs. The protocol was approved by the Western Institutional Review Board (2/8/2016; 20130084; ClinicalTrials.gov registration number: NCT02759900).
Five patients were enrolled after obtaining informed consent with 5 biopsy-proven and 12 clinically diagnosed AKs. The treatment protocol called for a single treatment using a NTAP device (described in detail by the authors previously 4 ) on the target lesions and 1 month follow-up without interval evaluation. The 1-month posttreatment results were evaluated clinically and by comparing pretreatment and follow-up photographs. The outcome was categorized as fully resolved when no visible or palpable lesions remained except minimal site erythema, significantly improved when there was at least 50% 
